News | November 11, 2021
Hester Biosciences to acquire 50 % stake in Thrishool Exim, Tanzania
The consideration for the acquisition is US $ 2.25 million
The consideration for the acquisition is US $ 2.25 million
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
The new facility will provide an important boost to vaccine capacity in Africa
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The preregistrations are aimed at registering both healthy children and those with comorbidities whereas preference will be given for children with comorbidities
Expertise in exosomes isolation and characterization will drive innovation in this field
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
